Article Text

Download PDFPDF
506 Consolidation courses in low-risk gestational trophoblastic neoplasia and relapse rate: a MITO-9 study
  1. Raffaella Cioffi1,
  2. Robert Fruscio2,3,
  3. Giulia Sabetta1,
  4. Daniela Giuliani3,
  5. Elisa Grassi1,
  6. Liliana Marchetta2,
  7. Alice Bergamini1,
  8. Cristina Dell’Oro2,
  9. Giovanna Scarfone4,
  10. Cristina Bonazzi3,
  11. Saverio Danese5,
  12. Gennaro Cormio6,7,
  13. Gabriella Ferrandina8,
  14. Sandro Pignata9 and
  15. Giorgia Mangili1
  1. 1San Raffaele Hospital, Milan, Italy
  2. 2University of Milan Bicocca, Milan, Italy
  3. 3San Gerardo dei Tintori Hospital, Monza, Italy
  4. 4Fondazione Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
  5. 5Sant’Anna Hospital, Turin, Italy
  6. 6Istituto Tumori, Bari, Italy
  7. 7University of Bari, Bari, Italy
  8. 8Fondazione Policlinico Universitario A. Gemelli – Catholic University, Rome, Italy
  9. 9Fondazione Pascale, National Cancer institute of Naples, Naples, Italy


Introduction/Background Methotrexate (MTX) is the gold standard treatment of gestational trophoblastic neoplasia (GTN), and it is usually administered until negative beta-human chorionic gonadotropin (hCG) levels, after which a variable number of consolidation courses is recommended. Aim of this study was to evaluate the relationship between the number of consolidation courses and relapse rate.

Methodology Patients with low-risk GTN treated with first-line MTX in 12 Italian centers between 1981 and 2021 were retrospectively identified and selected for the analysis. Exclusion criteria were exclusive surgical treatment, missing data on number of courses or non-standardized definitions of chemoresistance.

Results Among 435 patients treated for low-risk GTN, 333 patients were eligible for the analysis. In total, 98 patients (29.4%) switched to second-line treatment for chemoresistance. Seven patients (2.1%) relapsed after completion of first-line: 2 patients had a FIGO score of 5–6, 1 of 4, and the remaining lower than 4. Histological diagnosis in relapsed women was choriocarcinoma in 2 cases, hydatidiform mole in the remaining 5. Forty-one patients (17.4%) underwent 2 consolidation courses and had no relapse; 132 (56.1%) received 3 consolidation courses with a relapse rate of 2.2%; 39 patients (16.5%) received more than 3 consolidation courses with a relapse rate of 10.2%. Patients undergoing 2 consolidation courses had a FIGO score below 4 in 95% of cases.

Conclusion The number of consolidation courses after remission of low-risk GTN does not appear to have an impact on relapse rate. Probably, patients with lower scores can safely receive 2 courses of consolidation MTX. The higher relapse rate in patients who received more than 3 courses of MTX is explained by the higher score, and hence the higher risk of relapse, of these women.

Disclosures None.

Abstract 506 Table 1

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.